Vanda Pharmaceuticals (VNDA) Tops Q4 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Vanda Pharmaceuticals (VNDA) PT Lowered to $21 at Oppenheimer
February 14, 2019 8:10 AM ESTOppenheimer analyst Esther Rajavelu lowered the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $21.00 (from $29.00) while maintaining a Perform rating.
The analyst commented, "VNDA reported 4Q results that were higher than our estimates and provided 2019 guidance which came in below our (and... More
